X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-04-15 | REPL | Replimune Group, Inc. | Love Colin | COO | S - Sale | $30.63 | -30,000 | 895,809 | -3% | -$918,783 | ||||||
| D | 2021-04-15 | NSTG | Nanostring Technologies Inc | Hershberg Robert | Dir | S - Sale+OE | $73.91 | -144 | 1,890 | -7% | -$10,642 | |||||
| DM | 2021-04-15 | DTIL | Precision Biosciences Inc | Jantz Derek | Chief Scientific Officer | S - Sale+OE | $8.80 | -19,351 | 4,004,921 | 0% | -$170,289 | |||||
2021-04-16 | WINT | Windtree Therapeutics Inc /de/ | Hamill John P. | SVP, CFO | P - Purchase | $2.07 | +1,000 | 3,500 | +40% | +$2,067 | ||||||
2021-04-15 | WINT | Windtree Therapeutics Inc /de/ | Fraser Craig | Pres, CEO | P - Purchase | $2.24 | +1,000 | 29,445 | +4% | +$2,240 | ||||||
| M | 2021-04-14 | SWTX | Springworks Therapeutics, Inc. | Squinto Stephen P | Dir, 10% | S - Sale | $75.04 | -1,568 | 145,160 | -1% | -$117,655 | |||||
2021-04-14 | TARS | Tarsus Pharmaceuticals, Inc. | Vivo Capital Ix, LLC | 10% | S - Sale | $30.37 | -400 | 3,244,635 | 0% | -$12,148 | ||||||
| D | 2021-04-15 | ADPT | Adaptive Biotechnologies Corp | Lo Francis | Chief People Officer | S - Sale+OE | $43.04 | -2,000 | 23,104 | -8% | -$86,080 | |||||
| D | 2021-04-14 | ADPT | Adaptive Biotechnologies Corp | Baldo Lance | Chief Medical Officer | S - Sale+OE | $44.50 | -2,000 | 22,894 | -8% | -$89,000 | |||||
| D | 2021-04-14 | ADPT | Adaptive Biotechnologies Corp | Griffin Michelle Renee | Dir | S - Sale+OE | $43.41 | -4,500 | 1,504 | -75% | -$195,345 | |||||
2021-04-15 | JNCE | Jounce Therapeutics, Inc. | Higgons John Duncan | Dir | S - Sale | $10.00 | -200 | 9,713 | -2% | -$2,000 | ||||||
| D | 2021-04-15 | MRNA | Moderna, Inc. | Henderson Lori M. | GC, Secretary | S - Sale+OE | $158.76 | -6,600 | 901 | -88% | -$1,047,816 | |||||
| M | 2021-04-14 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $156.39 | -19,000 | 22,939,458 | 0% | -$2,971,350 | |||||
| D | 2021-04-14 | MRNA | Moderna, Inc. | Andres Juan | See remarks | S - Sale+OE | $153.75 | -5,000 | 0 | -100% | -$768,750 | |||||
| D | 2021-04-15 | ALLO | Allogene Therapeutics, Inc. | Bhavnagri Veer | GC | S - Sale+OE | $32.05 | -10,000 | 421,353 | -2% | -$320,517 | |||||
| M | 2021-04-13 | HARP | Harpoon Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | Former 10% Owner | S - Sale | $20.16 | -4,666 | 3,220,844 | 0% | -$94,075 | |||||
| M | 2021-04-13 | HARP | Harpoon Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $20.16 | -38,556 | 7,067,244 | -1% | -$777,359 | |||||
| D | 2021-04-12 | SRNE | Sorrento Therapeutics, Inc. | Janda Kim | Dir | S - Sale+OE | $6.97 | -1,900 | 3,000 | -39% | -$13,251 | |||||
| D | 2021-04-14 | AMGN | Amgen Inc | Sugar Ronald D | Dir | S - Sale+OE | $249.98 | -1,000 | 15,927 | -6% | -$249,980 | |||||
| D | 2021-04-13 | VIR | Vir Biotechnology, Inc. | Virgin Herbert | EVP, Research, CSO | S - Sale+OE | $43.57 | -5,560 | 88,200 | -6% | -$242,244 | |||||
| D | 2021-04-12 | TWST | Twist Bioscience Corp | Leproust Emily M. | Pres, CEO | S - Sale+OE | $128.71 | -2,000 | 265,843 | -1% | -$257,414 | |||||
| AD | 2021-03-30 | IKNA | Ikena Oncology, Inc. | Bonita David P | Dir | P - Purchase | $16.00 | +423,400 | 248,302 | -242% | +$6,774,400 | |||||
| D | 2021-04-12 | DTIL | Precision Biosciences Inc | Kane Matthew R. | Pres, CEO | S - Sale+OE | $8.67 | -9,741 | 1,975,637 | 0% | -$84,454 | |||||
2021-04-14 | HALO | Halozyme Therapeutics, Inc. | Kelley Kenneth J | Dir | S - Sale | $45.00 | -5,000 | 179,833 | -3% | -$225,000 | ||||||
| D | 2021-04-13 | MRNA | Moderna, Inc. | Henderson Lori M. | GC, Secretary | S - Sale+OE | $146.62 | -6,600 | 901 | -88% | -$967,692 | |||||
| DM | 2021-04-12 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $145.58 | -20,000 | 1,765,646 | -1% | -$2,911,600 | |||||
| D | 2021-04-12 | BDTX | Black Diamond Therapeutics, Inc. | Hatzis-Schoch Brent | See Remarks | S - Sale+OE | $25.00 | -4,078 | 8,400 | -33% | -$101,950 | |||||
| D | 2021-04-13 | SWTX | Springworks Therapeutics, Inc. | Smith L. Mary | Chief Development Officer | S - Sale+OE | $68.07 | -10,000 | 167,511 | -6% | -$680,723 | |||||
| M | 2021-03-16 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $66.03 | -26,863 | 169,803 | -14% | -$1,773,748 | |||||
| A | 2021-03-16 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $66.32 | -8,817 | 196,666 | -4% | -$584,743 | |||||
| A | 2021-03-10 | NSTG | Nanostring Technologies Inc | Gray R Bradley | Pres, CEO | S - Sale | $62.04 | -33,333 | 129,174 | -21% | -$2,068,062 | |||||
2021-03-25 | NSTG | Nanostring Technologies Inc | Brown J. Chad | SVP, Sales, Marketing | S - Sale | $68.78 | -4,948 | 0 | -100% | -$340,323 | ||||||
| A | 2021-03-16 | NSTG | Nanostring Technologies Inc | Brown J. Chad | SVP, Sales, Marketing | S - Sale | $66.32 | -1,335 | 9,702 | -12% | -$88,537 | |||||
| M | 2021-03-16 | NSTG | Nanostring Technologies Inc | Beechem Joseph M | SVP, Research, Development | S - Sale | $66.00 | -10,035 | 80,035 | -11% | -$662,327 | |||||
| A | 2021-03-16 | NSTG | Nanostring Technologies Inc | Beechem Joseph M | SVP, Research, Development | S - Sale | $66.32 | -1,778 | 90,070 | -2% | -$117,917 | |||||
2021-03-16 | NSTG | Nanostring Technologies Inc | Bailey K Thomas | CFO | S - Sale | $66.32 | -1,161 | 18,155 | -6% | -$76,998 | ||||||
| A | 2021-03-16 | NSTG | Nanostring Technologies Inc | Bailey K Thomas | CFO | S - Sale | $66.32 | -1,335 | 19,316 | -6% | -$88,537 | |||||
| AD | 2021-03-30 | IKNA | Ikena Oncology, Inc. | Orbimed Advisors LLC | Dir | P - Purchase | $16.00 | +423,400 | 248,302 | -242% | +$6,774,400 | |||||
2021-04-09 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $29.99 | -119 | 3,665,787 | 0% | -$3,569 | ||||||
2021-04-09 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $29.99 | -119 | 3,665,787 | 0% | -$3,569 | ||||||
2021-04-09 | ITOS | Iteos Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $29.99 | -200 | 6,004,368 | 0% | -$5,998 | ||||||
| D | 2021-04-12 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $138.96 | -5,000 | 0 | -100% | -$694,818 | |||||
| M | 2021-04-09 | HARP | Harpoon Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $21.90 | -30,928 | 7,105,800 | 0% | -$677,357 | |||||
| D | 2021-04-12 | MRNA | Moderna, Inc. | Andres Juan | See remarks | S - Sale+OE | $142.46 | -5,000 | 0 | -100% | -$712,300 | |||||
| M | 2021-04-09 | HARP | Harpoon Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $23.15 | -12,796 | 3,225,510 | 0% | -$296,261 | |||||
2021-04-09 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $140.91 | -11,046 | 22,960,458 | 0% | -$1,556,482 | ||||||
| DM | 2021-04-08 | KYMR | Kymera Therapeutics, Inc. | Mainolfi Nello | CEO | S - Sale+OE | $33.62 | -48,000 | 376,199 | -11% | -$1,613,563 | |||||
2021-04-09 | EIGR | Eiger Biopharmaceuticals, Inc. | Dietz Thomas John | Dir | P - Purchase | $8.49 | +2,500 | 37,500 | +7% | +$21,220 | ||||||
| M | 2021-04-08 | RVMD | Revolution Medicines, Inc. | Svennilson Peter | Dir | S - Sale | $44.46 | -70,929 | 3,206,085 | -2% | -$3,153,745 | |||||
| DM | 2021-04-08 | DTIL | Precision Biosciences Inc | Kane Matthew R. | Pres, CEO | S - Sale+OE | $8.94 | -19,473 | 1,963,864 | -1% | -$173,991 | |||||
| DM | 2021-04-08 | SGEN | Seagen Inc. | Siegall Clay B | Pres, CEO | S - Sale+OE | $143.79 | -29,353 | 715,209 | -4% | -$4,220,740 | |||||
| M | 2021-04-07 | ITOS | Iteos Therapeutics, Inc. | Gadicke Ansbert | 10% | S - Sale | $30.99 | -41,982 | 6,004,568 | -1% | -$1,300,850 | |||||
| D | 2021-04-08 | MRNA | Moderna, Inc. | Henderson Lori M. | GC, Secretary | S - Sale+OE | $132.85 | -6,600 | 901 | -88% | -$876,810 | |||||
| M | 2021-04-07 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $132.27 | -19,000 | 22,971,504 | 0% | -$2,513,170 | |||||
| M | 2021-04-07 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2014, L.P. | 10% | S - Sale | $30.99 | -25,087 | 3,655,906 | -1% | -$777,343 | |||||
| M | 2021-04-07 | ITOS | Iteos Therapeutics, Inc. | Mpm Bioventures 2018, L.P. | 10% | S - Sale | $30.99 | -25,087 | 3,655,906 | -1% | -$777,343 | |||||
2021-04-07 | ADPT | Adaptive Biotechnologies Corp | Adams R Mark | COO | S - Sale | $42.34 | -3,586 | 67,018 | -5% | -$151,831 | ||||||
| DM | 2021-04-06 | ADPT | Adaptive Biotechnologies Corp | Cohen Chad M | CFO | S - Sale+OE | $41.30 | -20,000 | 21,604 | -48% | -$826,005 | |||||
| M | 2021-04-06 | ADPT | Adaptive Biotechnologies Corp | Robins Chad M | CEO, COB | S - Sale | $41.81 | -15,000 | 1,748,461 | -1% | -$627,107 | |||||
| D | 2021-04-07 | ALEC | Alector, Inc. | Paul Robert | Chief Medical Officer | S - Sale+OE | $19.20 | -22,300 | 213,719 | -9% | -$428,050 | |||||
2021-04-06 | RGEN | Repligen Corp | Bylund James | SVP, Global Operations, IT | S - Sale | $204.25 | -360 | 6,324 | -5% | -$73,530 | ||||||
2021-04-07 | WINT | Windtree Therapeutics Inc /de/ | Curtis Eric | SVP, COO | P - Purchase | $2.52 | +791 | 1,291 | +158% | +$1,991 | ||||||
| D | 2021-04-07 | MRNA | Moderna, Inc. | Andres Juan | See remarks | S - Sale+OE | $131.63 | -5,000 | 0 | -100% | -$658,150 | |||||
| D | 2021-04-06 | MRNA | Moderna, Inc. | Henderson Lori M. | GC, Secretary | S - Sale+OE | $130.01 | -6,600 | 901 | -88% | -$858,066 | |||||
| D | 2021-04-05 | TWST | Twist Bioscience Corp | Finn Patrick John | Chief Commercial Officer | S - Sale+OE | $126.72 | -2,702 | 42,744 | -6% | -$342,397 | |||||
| M | 2021-04-05 | RVMD | Revolution Medicines, Inc. | Svennilson Peter | Dir | S - Sale | $46.96 | -85,668 | 3,243,704 | -3% | -$4,023,041 | |||||
2021-04-05 | VYGR | Voyager Therapeutics, Inc. | Hesslein Robert W. | SVP, GC | S - Sale | $4.95 | -3,292 | 110,056 | -3% | -$16,295 | ||||||
| D | 2021-04-05 | BDTX | Black Diamond Therapeutics, Inc. | Roberts Christopher D. | Chief Scientific Officer | S - Sale+OE | $25.54 | -2,500 | 3,200 | -44% | -$63,848 | |||||
| DM | 2021-04-05 | NVAX | Novavax Inc | Trizzino John | EVP, Chief Commercial Officer | S - Sale+OE | $189.38 | -3,212 | 287 | -92% | -$608,296 | |||||
2021-04-05 | BLUE | Bluebird Bio, Inc. | Obenshain Andrew | Pres of SGD | S - Sale | $30.21 | -29 | 40,137 | 0% | -$876 | ||||||
2021-04-05 | BLUE | Bluebird Bio, Inc. | Leschly Nick | Pres, CEO | S - Sale | $30.21 | -444 | 475,835 | 0% | -$13,411 | ||||||
2021-04-05 | BLUE | Bluebird Bio, Inc. | Gregory Philip D | Chief Scientific Officer | S - Sale | $30.21 | -39 | 46,868 | 0% | -$1,178 | ||||||
2021-04-05 | BLUE | Bluebird Bio, Inc. | Cole Jason | COO and | S - Sale | $30.21 | -37 | 47,960 | 0% | -$1,118 | ||||||
2021-04-05 | BLUE | Bluebird Bio, Inc. | Davidson David | Chief Medical Officer | S - Sale | $30.21 | -42 | 47,787 | 0% | -$1,269 | ||||||
2021-04-05 | ATRA | Atara Biotherapeutics, Inc. | Newell Joe | Chief Operations Officer | S - Sale | $14.74 | -655 | 134,924 | 0% | -$9,655 | ||||||
2021-04-06 | WINT | Windtree Therapeutics Inc /de/ | Fraser Craig | Pres, CEO | P - Purchase | $2.57 | +500 | 28,445 | +2% | +$1,285 | ||||||
2021-04-05 | XFOR | X4 Pharmaceuticals, Inc | Ragan Paula | Pres, CEO | S - Sale | $9.17 | -2,400 | 415,152 | -1% | -$22,008 | ||||||
2021-04-05 | DNLI | Denali Therapeutics Inc. | Schuth Alexander O. | COO, Secretary | S - Sale | $56.09 | -10,000 | 612,626 | -2% | -$560,901 | ||||||
| D | 2021-04-05 | CCCC | C4 Therapeutics, Inc. | Crystal Adam | Chief Medical Officer | S - Sale+OE | $37.77 | -15,000 | 0 | -100% | -$566,536 | |||||
2021-04-05 | WINT | Windtree Therapeutics Inc /de/ | Fraser Craig | Pres, CEO | P - Purchase | $2.58 | +1,000 | 27,945 | +4% | +$2,580 | ||||||
| D | 2021-04-05 | MRNA | Moderna, Inc. | Zaks Tal Zvi | Chief Medical Officer | S - Sale+OE | $129.71 | -5,000 | 0 | -100% | -$648,530 | |||||
| D | 2021-04-05 | MRNA | Moderna, Inc. | Andres Juan | See remarks | S - Sale+OE | $132.63 | -5,000 | 0 | -100% | -$663,150 | |||||
| D | 2021-04-05 | MRNA | Moderna, Inc. | Hoge Stephen | Pres | S - Sale+OE | $132.63 | -20,000 | 1,765,646 | -1% | -$2,652,600 | |||||
2021-04-05 | MRNA | Moderna, Inc. | Bancel Stephane | CEO | S - Sale | $129.77 | -11,046 | 22,992,504 | 0% | -$1,433,417 | ||||||
| D | 2021-04-05 | XLRN | Acceleron Pharma Inc | Zakrzewski Joseph S | Dir | S - Sale+OE | $140.73 | -10,000 | 34,499 | -22% | -$1,407,343 | |||||
| D | 2021-04-05 | XLRN | Acceleron Pharma Inc | Smith Karen L. | Dir | S - Sale+OE | $140.19 | -11,864 | 1,622 | -88% | -$1,663,156 | |||||
| D | 2021-04-05 | HALO | Halozyme Therapeutics, Inc. | Torley Helen | Pres, CEO | S - Sale+OE | $42.55 | -50,000 | 537,160 | -9% | -$2,127,250 | |||||
| M | 2021-04-01 | PSTX | Poseida Therapeutics, Inc. | Ostertag Eric | CEO, 10% | S - Sale | $9.61 | -115,000 | 5,866,944 | -2% | -$1,104,998 | |||||
| M | 2021-01-05 | CDTX | Cidara Therapeutics, Inc. | Abdollahian Neil | Chief Business Officer | S - Sale | $2.26 | -4,337 | 57,471 | -7% | -$9,816 | |||||
| M | 2021-01-05 | CDTX | Cidara Therapeutics, Inc. | Daruwala Paul | COO | S - Sale | $2.16 | -3,461 | 50,531 | -6% | -$7,485 | |||||
| M | 2021-01-05 | CDTX | Cidara Therapeutics, Inc. | Oien Jessica | GC, Secretary | S - Sale | $2.41 | -2,001 | 7,764 | -20% | -$4,828 | |||||
| D | 2021-04-01 | HARP | Harpoon Therapeutics, Inc. | Wesche Holger | Chief Scientific Officer | S - Sale+OE | $20.45 | -10,000 | 52,852 | -16% | -$204,491 | |||||
| D | 2021-04-01 | VIR | Vir Biotechnology, Inc. | Parrish Jay | Chief Business Officer | S - Sale+OE | $51.40 | -6,944 | 9,260 | -43% | -$356,956 | |||||
2021-04-01 | DNLI | Denali Therapeutics Inc. | Tessier-Lavigne Marc | Dir | S - Sale | $56.62 | -50,000 | 2,592,296 | -2% | -$2,831,071 | ||||||
2021-04-01 | DNLI | Denali Therapeutics Inc. | Watts Ryan J. | Pres, CEO | S - Sale | $56.60 | -18,334 | 2,404,099 | -1% | -$1,037,684 | ||||||
2021-04-01 | WINT | Windtree Therapeutics Inc /de/ | Fraser Craig | Pres, CEO | P - Purchase | $2.46 | +500 | 26,945 | +2% | +$1,229 | ||||||
| D | 2021-03-31 | ADPT | Adaptive Biotechnologies Corp | Taylor Stacy L | SVP, GC | S - Sale+OE | $40.00 | -4,167 | 15,036 | -22% | -$166,680 | |||||
| D | 2021-04-01 | EXEL | Exelixis, Inc. | Lamb Peter | EVP, Scientific Strategy, CSO | S - Sale+OE | $22.96 | -60,000 | 406,572 | -13% | -$1,377,600 | |||||
| D | 2021-04-01 | EXEL | Exelixis, Inc. | Schwab Gisela | Pres, Prod Dev, Med Aff, CMO | S - Sale+OE | $23.00 | -50,000 | 628,362 | -7% | -$1,150,000 | |||||
| D | 2021-04-01 | XLRN | Acceleron Pharma Inc | Zakrzewski Joseph S | Dir | S - Sale+OE | $134.64 | -10,000 | 34,499 | -22% | -$1,346,382 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |